223 related articles for article (PubMed ID: 16880230)
1. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer.
Pietras RJ
Oncologist; 2006; 11(7):704-17. PubMed ID: 16880230
[TBL] [Abstract][Full Text] [Related]
2. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
3. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
4. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
5. New strategies in estrogen receptor-positive breast cancer.
Johnston SR
Clin Cancer Res; 2010 Apr; 16(7):1979-87. PubMed ID: 20332324
[TBL] [Abstract][Full Text] [Related]
6. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
7. Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Lane HA; Lebwohl D
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S18-25. PubMed ID: 16730273
[TBL] [Abstract][Full Text] [Related]
8. The NFkappaB pathway and endocrine-resistant breast cancer.
Zhou Y; Eppenberger-Castori S; Eppenberger U; Benz CC
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S37-46. PubMed ID: 16113098
[TBL] [Abstract][Full Text] [Related]
9. Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
Schiff R; Massarweh SA; Shou J; Bharwani L; Arpino G; Rimawi M; Osborne CK
Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():10-20. PubMed ID: 16273359
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
Schiff R; Massarweh S; Shou J; Osborne CK
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):447S-54S. PubMed ID: 12538499
[TBL] [Abstract][Full Text] [Related]
11. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer?
Bedard PL; Freedman OC; Howell A; Clemons M
Breast Cancer Res Treat; 2008 Apr; 108(3):307-17. PubMed ID: 18351454
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor: current understanding of its activation and modulation.
Osborne CK; Schiff R; Fuqua SA; Shou J
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4338s-4342s; discussion 4411s-4412s. PubMed ID: 11916222
[TBL] [Abstract][Full Text] [Related]
13. [Hormone resistance and its modulation in breast cancer].
Kahán Z; Thurzó L
Orv Hetil; 2005 Apr; 146(16):731-7. PubMed ID: 15889669
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.
Lee AV; Cui X; Oesterreich S
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4429s-4435s; discussion 4411s-4412s. PubMed ID: 11916236
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
16. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer.
Cleator SJ; Ahamed E; Coombes RC; Palmieri C
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S6-S17. PubMed ID: 19561006
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
18. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy.
Osborne CK; Schiff R; Arpino G; Lee AS; Hilsenbeck VG
Breast; 2005 Dec; 14(6):458-65. PubMed ID: 16236516
[TBL] [Abstract][Full Text] [Related]
19. Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer.
Johnston SR
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1061s-1068s. PubMed ID: 16467125
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
